Clinical trial · Observational
MRinRT: Swansea University and SWWCC Collaboration Study.
Developing and Optimising the Use of Magnetic Resonance Imaging and Spectroscopy in Radiotherapy (MRinRT) Pathways: Investigating Avenues to Improve Outcomes for Patients and the Assessment of Treatment Response.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone. The main questions it aims to answer is: * Can MRI scan images be adjusted to make the tumour and normal tissues easier to see? * Does adding MRI to a radiotherapy planning CT make the radiotherapy plan more precise? * Can MRI be used to adjust a radiotherapy plan during a course of treatment to make it more precise, and might that reduce the side effects? * Are there particular MRI scans that can predict how a tumour will respond to radiotherapy or how likely the patient is to have side effects? This study will assess current MRI scanning procedures and ensure these are adjusted to best suit radiotherapy planning. It will also provide pilot data evaluating: 1. MRI-adapted radiotherapy Usually, radiotherapy plans are based on a pre-treatment planning CT scan. Unless an issue is detected the patient would complete their whole course of radiotherapy on this plan. This does not account for changes in position/size/shape of the tumour that occur over the whole treatment course. Clinicians therefore increase the size of the tumour/target to account for these uncertainties, which can increase side effects. This study will assess the potential to reduce side effects from radiotherapy by using repeat MRI scans and replanning during the treatment course (MRI-adaptive radiotherapy). 2. Imaging biomarkers MRI sequences can be used to predict response to radiotherapy or chance of developing side effects. This study will identify potential MRI sequences that may be used as imaging biomarkers, to guide the development of future clinical trials. The study will be undertaken at SBUHB, lasting 4 years, and involving ≤15 healthy volunteers and ≤150 patients.
Conditions
Conditions (11)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain (Nervous System) Cancers | — | UNRESOLVED | — |
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| MRI | — | UNRESOLVED | — |
| MRI-guided Adaptive Radiotherapy | — | UNRESOLVED | — |
| MRI Image Enhancement | — | UNRESOLVED | — |
| MRI Scanner Configuration | — | UNRESOLVED | — |
| Oesophageal Carcinoma | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Healthy Volunteer
- description
- Volunteers with no history of any medical issue which may affect the scan interpretation and who are eligible for MRI scanning
- interventionNames
- Other: MRI
- label
- Patient
- description
- Patients with the tumour of interest who are due to undergo radiotherapy and are eligible for MRI scanning
- interventionNames
- Other: MRI
Primary outcomes (7)
- measure
- Optimisation of MRI images 1
- timeFrame
- From enrolment to analysis, on average 4-6 weeks
- description
- Participant acceptability with average rating of 4 or higher on the Participant Questionnaire MRI Section Q1 and Q2
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria for health volunteers: * Free from medical conditions that could confound imaging or study results * Eligible for MRI Inclusion Criteria for patients: * Confirmed diagnosis of invasive carcinoma at the relevant tumour/target sites listed in this protocol * Scheduled to receive radiotherapy to the target site * ECOG performance status of 0-2 * Eligible for MRI (determined through MRI safety screening) Exclusion Criteria: * Presence of medical conditions that may interfere with study outcomes or data interpretation * Use of regular medications that could affect imaging results or safety * Any contraindications to MRI scanning, including but not limited to claustrophobia, reduced thermal regulatory capabilities, MR Unsafe implants and foreign bodies.
References
Publications (4)
- BACKGROUNDKeall P, Poulsen P, Booth JT. See, Think, and Act: Real-Time Adaptive Radiotherapy. Semin Radiat Oncol. 2019 Jul;29(3):228-235. doi: 10.1016/j.semradonc.2019.02.005. PMID 31027640
- BACKGROUNDHunt A, Hansen VN, Oelfke U, Nill S, Hafeez S. Adaptive Radiotherapy Enabled by MRI Guidance. Clin Oncol (R Coll Radiol). 2018 Nov;30(11):711-719. doi: 10.1016/j.clon.2018.08.001. Epub 2018 Sep 7. PMID 30201276
- BACKGROUNDBakke KM, Hole KH, Dueland S, Groholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR. Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival. Acta Oncol. 2017 Jun;56(6):813-818. doi: 10.1080/0284186X.2017.1287951. Epub 2017 Feb 17. PMID 28464745
- BACKGROUNDHuddart R et al, Protocol for Development of daily online magnetic resonance imaging for magnetic resonance image guided radiotherapy, IRAS ID 208449, version 6.0 22/2/2024